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A B S T R A C T
Purpose
The phase III CRYSTAL study demonstrated that addition of cetuximab to fluorouracil, leucovorin,
and irinotecan (FOLFIRI) significantly improved overall survival, progression-free survival, and
objective response in the first-line treatment of patients with KRAS codon 12/13 (exon 2) wild-type
metastatic colorectal cancer (mCRC). Outcome was reassessed in subgroups defined by extended
RAS mutation testing.
Patients and Methods
Existing DNA samples from KRAS exon 2 wild-type tumors from CRYSTAL study patients were
reanalyzed for other RAS mutations in four additional KRAS codons (exons 3 and 4) and six NRAS
codons (exons 2, 3, and 4) using beads, emulsion, amplification, and magnetics technology. No
tissue microdissection was performed. A  5% mutant allele cutoff was used to call mutations.
Results
Mutation status was evaluable in 430 (64.6%) of 666 patients with KRAS exon 2 wild-type
tumors. Other RAS mutations were detected in 63 (14.7%) of 430 patients. In those with RAS
wild-type tumors, a significant benefit across all efficacy end points was associated with the
addition of cetuximab to FOLFIRI. In patients with other RAS tumor mutations, no difference
in efficacy outcomes between treatment groups was seen. The safety profile in RAS
subgroups was similar and in line with expectations.
Conclusion
In the first-line treatment of mCRC, patients with RAS wild-type tumors derived a significant
benefit from the addition of cetuximab to FOLFIRI; patients with RAS tumor mutations did not.
Molecular testing of tumors for all activating RAS mutations is essential before considering
anti–epidermal growth factor receptor therapy, thereby allowing the further tailoring of cetuximab
administration to maximize patient benefit.
J Clin Oncol 33:692-700. © 2015 by American Society of Clinical Oncology
INTRODUCTION
The randomized phase III CRYSTAL (Cetuximab
Combined With Irinotecan in First-Line Therapy
forMetastaticColorectalCancer) study showed that
the additionof cetuximab to infusional fluorouracil,
leucovorin,andirinotecan(FOLFIRI)significantlyim-
proved overall survival (OS) time, progression-free
survival (PFS) time, and objective response rate in the
first-line treatment of patients with KRAS codon 12
and 13 (hereinafter exon 2) wild-typemetastatic colo-
rectal cancer (mCRC). No cetuximab efficacy benefit
wasapparentinthesubgroupofpatientswhosetumors
carried such exon 2mutations.1,2
In the same setting, the randomized phase II
OPUS (Oxaliplatin and Cetuximab in First-Line
Treatment of Metastatic Colorectal Cancer) study
demonstrated that the addition of cetuximab to
anotherstandardfirst-lineregimen—fluorouracil, leu-
covorin, and oxaliplatin (FOLFOX4)—significantly
improved objective response rate and PFS time in
patients withKRAS exon 2wild-type tumors. How-
ever, it was reported that for patients with KRAS
exon 2 tumormutations, the addition of cetuximab
to FOLFOX4 resulted in worse outcome compared
with FOLFOX4 alone.3,4 Similar findings were also
reported from the PRIME (Panitumumab Ran-
domizedTrial inCombinationWithChemotherapy
forMetastatic Colorectal Cancer to Determine Effi-
cacy) study for another epidermal growth factor re-
ceptor (EGFR) antibody, panitumumab, which
improvedoutcome inpatientswhencombinedwith
FOLFOX4in thefirst-line treatmentofKRASexon2
wild-typemCRC.As for cetuximab, anegative effect
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was apparent when panitumumab was combined with FOLFOX4 in
patients with KRAS exon 2mutations.5
Activatingmissensemutations of KRAS at codons other than 12
or 13 have been identified in a wide range of tumor types, including
CRC.6 Similar somatic tumor mutations have also been detected at
corresponding loci within the NRAS gene. A retrospective analysis of
the PRIME study demonstrated that a subgroup of 17.4% of patients
with KRAS exon 2 wild-typemCRC had tumormutations at another
RAS locus (KRAS codons 61, 117, and 146; NRAS codons 12, 13, and
61). Such other RAS mutations were associated negatively with out-
come in patients receiving FOLFOX4 plus panitumumab.7 Explor-
atory analysis further suggested that RAS codon 59 mutations might
also be negative biomarkers for panitumumab efficacy.
The primary objective of our post hoc investigationwas to assess
the treatment effect of FOLFIRI plus cetuximab compared with
FOLFIRIalone inpatientswith tumors carryingpredefinedmutations
at RAS loci other than KRAS codon 12 or 13 (other RAS mutations).
Also assessed was the treatment effect in patients with evaluable tu-
mors wild type at all RAS loci.
PATIENTS AND METHODS
Study Design and Treatment
The phase III CRYSTAL study compared 14-day cycles of FOLFIRI plus
weekly cetuximabwith FOLFIRI alone as first-line treatment for patients with
EGFR-expressingmCRC.Treatmentwas continueduntil disease progression,
unacceptable toxicity, or withdrawal of consent. The primary end point was
PFS, asdeterminedby independent review.The clinical studywas approvedby
the independent ethics committee of each trial center and was carried out in
accordance with the Declaration of Helsinki. Eligibility criteria have been
described previously.1 All patients provided informed consent before inclu-
sion.Aprevious retrospective subgroupanalysis investigated theassociationof
tumor KRAS exon 2mutation status and treatment outcome.2
RAS Mutation Testing
Extended RAS mutation testing was performed on DNA samples ex-
tracted previously from formalin-fixed paraffin-embedded tumor tissue sec-
tions from CRYSTAL study patients and which had been scored in earlier
investigations as wild type at codons 12 and 13 ofKRAS.2 BeforeDNA extrac-
tion, stainedslideswere reviewedbyapathologist toestimateoverallneoplastic
cell content; no exclusion criteria were applied. The estimated fraction of
neoplastic cells was between 5% and 60% for most samples. Because the
polymerase chain reaction clamping andmelting curve technique used in the
original testing was a highly sensitive method designed to enrich for mutant
over wild-type sequences,1,8 macro- or microdissection of tissue sections was
not carried out. In the application of the 5% cutoff in our analysis, the esti-
mated fraction of neoplastic cells was not taken into consideration. Ploidy
status, which was not assessed, was also not taken into consideration.
The highly sensitive beads, emulsion, amplification, and magnetics
(BEAM) technologywas selected for theRASmutation analysis to take into
account the source and nature of the tumor DNA available (Data Supple-
ment).9 This approach can detect and enumerate mutant versus wild-type
DNA sequences at ratios down to 1:10,000 (0.01%).10,11 RAS testing was
carried out by a contract research organization (Sysmex Inostics, Ham-
burg, Germany).
Randomly assigned and treated
Modified intention-to-treat population
(N = 1,198)
FOLFIRI plus cetuximab
(n = 599)
FOLFIRI alone
(n = 599)
Tumors evaluable for KRAS
codon 12/13 status
(n = 530)
KRAS codon
12/13 wild type
(n = 316)
KRAS codon
12/13 mutant
(n = 214)
KRAS codon
12/13 wild type
(n = 350)
Evaluable for
RAS status
(n = 210)
RAS
wild type
(n = 178)
Other RAS
mutant
(n = 32)
Any RAS
mutant
(n = 246)
RAS
wild type
(n = 189)
Other RAS
mutant
(n = 31)
Any RAS
mutant
(n = 214)
Evaluable for
RAS status
(n = 220)
KRAS codon
12/13 mutant
(n = 183)
Tumors evaluable for KRAS
codon 12/13 status
(n = 533)
Fig 1. Study profile. FOLFIRI, fluoroura-
cil, leucovorin, and irinotecan.
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Table 1. Baseline Demographic and Clinical Characteristics of KRAS Exon 2 Wild-Type Subgroup of KRAS Population and RAS Subpopulations
Characteristic
KRAS Exon 2 Wild Type
Any RAS Mutation
(n  460)
Overall
(N  666)
RAS Evaluable
(n  430)
RAS Wild Type
(n  367)
Other RAS Mutations
(n  63)
FOLFIRI

Cetuximab
(n  316)
FOLFIRI
(n  350)
FOLFIRI

Cetuximab
(n  210)
FOLFIRI
(n  220)
FOLFIRI

Cetuximab
(n  178)
FOLFIRI
(n  189)
FOLFIRI

Cetuximab
(n  32)
FOLFIRI
(n  31)
FOLFIRI

Cetuximab
(n  246)
FOLFIRI
(n  214)
No. % No. % No. % No. % No. % No. % No. % No. % No. % No. %
Sex
Male 196 62.0 211 60.3 130 61.9 137 62.3 109 61.2 120 63.5 21 65.6 17 54.8 152 61.8 123 57.5
Female 120 38.0 139 39.7 80 38.1 83 37.7 69 38.8 69 36.5 11 34.4 14 45.2 94 38.2 91 42.5
Age, years
Median 61.0 59.0 60.0 59.0 60.0 59.0 61.5 60.0 62.0 63.0
Range 24.0-79.0 19.0-84.0 24.0-79.0 19.0-82.0 24.0-79.0 19.0-82.0 28.0-75.0 30.0-78.0 22.0-80.0 30.0-83.0
Region
Western Europe 145 45.9 158 45.1 103 49.0 107 48.6 86 48.3 95 50.3 17 53.1 12 38.7 110 44.7 96 44.9
Eastern Europe 115 36.4 123 35.1 75 35.7 70 31.8 63 35.4 56 29.6 12 37.5 14 45.2 88 35.8 80 37.4
Outside Europe 56 17.7 69 19.7 32 15.2 43 19.5 29 16.3 38 20.1 3 9.4 5 16.1 48 19.5 38 17.8
ECOG PS
0 183 57.9 200 57.1 116 55.2 131 59.5 97 54.5 114 60.3 19 59.4 17 54.8 143 58.1 108 50.5
1 120 38.0 136 38.9 85 40.5 80 36.4 76 42.7 68 36.0 9 28.1 12 38.7 92 37.4 101 47.2
2 13 4.1 14 4.0 9 4.3 9 4.1 5 2.8 7 3.7 4 12.5 2 6.5 11 4.5 5 2.3
Duration of mCRC, months
Mean 3.4 2.5 3.4 2.6 3.6 2.5 2.3 3.2 3.1 2.2
SD 8.3 4.9 8.6 5.2 9.3 5.1 1.5 5.9 5.4 3.0
Median 1.6 1.5 1.6 1.6 1.6 1.6 2.0 1.6 1.7 1.6
Range 0-92 0-66 0-92 0-66 0-92 0-66 0-7 0-32 0-43 0-32
Prior adjuvant chemotherapy 80 25.3 73 20.9 48 22.9 44 20.0 40 22.5 42 22.2 8 25.0 2 6.5 40 16.3 28 13.1
No. of metastatic sites
 2 277 87.7 295 84.3 183 87.1 187 85.0 157 88.2 161 85.2 26 81.3 26 83.9 209 85.0 179 83.6
 2 33 10.4 49 14.0 23 11.0 30 13.6 17 9.6 25 13.2 6 18.8 5 16.1 35 14.2 33 15.4
Missing 6 1.9 6 1.7 4 1.9 3 1.4 4 2.2 3 1.6 0 0.0 0 0.0 2 0.8 2 0.9
Metastases confined to liver 68 21.5 72 20.6 47 22.4 52 23.6 43 24.2 46 24.3 4 12.5 6 19.4 49 19.9 56 26.2
Longest diameter of index lesion
 Median 165 52.2 184 52.6 112 53.3 119 54.1 92 51.7 101 53.4 20 62.5 18 58.1 126 51.2 106 49.5
 Median 150 47.5 164 46.9 98 46.7 99 45.0 86 48.3 87 46.0 12 37.5 12 38.7 119 48.4 105 49.1
Missing 1 0.3 2 0.6 0 0.0 2 0.9 0 0.0 1 0.5 0 0.0 1 3.2 1 0.4 3 1.4
Tumor site
Colon 183 57.9 204 58.3 124 59.0 132 60.0 106 59.6 117 61.9 18 56.3 15 48.4 153 62.2 131 61.2
Rectum 127 40.2 140 40.0 81 38.6 85 38.6 68 38.2 70 37.0 13 40.6 15 48.4 86 35.0 79 36.9
Colon and rectum 6 1.9 6 1.7 5 2.4 3 1.4 4 2.2 2 1.1 1 3.1 1 3.2 6 2.4 4 1.9
Missing 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.4 0 0.0
Tumor localization
Left sided 246 77.8 267 76.3 164 78.1 165 75.0 142 79.8 138 73.0 22 68.8 27 87.1 164 66.7 152 71.0
Right sided 64 20.3 80 22.9 42 20.0 55 25.0 33 18.5 51 27.0 9 28.1 4 12.9 76 30.9 62 29.0
Left and right sided 6 1.9 3 0.9 4 1.9 0 0.0 3 1.7 0 0.0 1 3.1 0 0.0 5 2.0 0 0.0
Missing 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.4 0 0.0
Alkaline phosphatase, U/L
 300 30 9.5 42 12.0 25 11.9 18 8.2 22 12.4 17 9.0 3 9.4 1 3.2 33 13.4 24 11.2
 300 272 86.1 295 84.3 177 84.3 191 86.8 150 84.3 163 86.2 27 84.4 28 90.3 203 82.5 175 81.8
Missing 14 4.4 13 3.7 8 3.8 11 5.0 6 3.4 9 4.8 2 6.3 2 6.5 10 4.1 15 7.0
Leucocytes, per L
 10,000 258 81.6 284 81.1 176 83.8 181 82.3 150 84.3 154 81.5 26 81.3 27 87.1 200 81.3 160 74.8
 10,000 48 15.2 58 16.6 27 12.9 32 14.5 22 12.4 29 15.3 5 15.6 3 9.7 38 15.4 50 23.4
Missing 10 3.2 8 2.3 7 3.3 7 3.2 6 3.4 6 3.2 1 3.1 1 3.2 8 3.3 4 1.9
Lactate dehydrogenase
 ULN 138 43.7 150 42.9 97 46.2 87 39.5 84 47.2 73 38.6 13 40.6 14 45.2 107 43.5 99 46.3
 ULN 144 45.6 161 46.0 90 42.9 110 50.0 74 41.6 96 50.8 16 50.0 14 45.2 116 47.2 87 40.7
Missing 34 10.8 39 11.1 23 11.0 23 10.5 20 11.2 20 10.6 3 9.4 3 9.7 23 9.3 28 13.1
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; FOLFIRI, fluorouracil, leucovorin, and irinotecan; mCRC, metastatic colorectal
cancer; SD, standard deviation; ULN, upper normal limit.
Right sided: appendix, cecum, ascending colon, hepatic flexure, and transverse colon. Left sided: splenic flexure, descending colon, sigmoid colon, and rectum.
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The presence of 26 specific mutations reported in the Catalogue of
Somatic Mutations in Cancer and/or Cancer Genome Atlas databases within
KRAS exons 3 (codons 59 and 61) and 4 (codons 117 and 146) and NRAS
exons 2 (codons 12 and13), 3 (codons 59 and61), and4 (codons 117 and146)
was investigated (Data Supplement). Samples were not reassessed for the
presence of KRAS exon 2 (codons 12 and 13) mutations.
Statistical Analysis
For each evaluable sample, the fraction of mutant RAS alleles was
calculated by dividing the number of mutant beads by the total number of
beads with polymerase chain reaction product (sum of mutant, wild-type,
and mutant/wild-type beads). Broadly in line with the sensitivity of other
approaches thatmight be used clinically to assignRASmutation status, and
after an initial evaluation of the impact of using alternative cutoff values,
tumors were scored asRASmutant if the sumof the individual percentages
of mutant sequences over total amplified sequences for the analyzed loci
was 5%, regardless of whether all loci were evaluable formutation status.
Tumors were scored as RAS wild type only if all 26 mutation assays were
evaluable and the summed prevalence of mutations across all loci
was 5%.
The primary objective of our post hoc analysis was to investigate the
treatment effect of FOLFIRI plus cetuximab comparedwith FOLFIRI alone in
patientswith tumorRASmutationsother thanKRAS exon2(otherRAS).This
extended analysis was limited to those CRYSTAL study patients for whom an
evaluable tumor DNA sample was available. Outcome for patients with tu-
morswild type at all testedRAS loci was also investigated. Treatment outcome
in patients with any RAS mutation, comprising those with either previously
identified KRAS exon 2mutations (not reassessed in our study) or other RAS
mutations,was also analyzed.Outcome inpatientswild type for bothRAS and
BRAF (V600E; as previously defined2)was considered. The treatment effect in
different other RAS-mutant populations, as defined according to a range of
diagnostic cutoffs from 0.1% to 20%, was visualized using forest plots of
hazard ratios (HRs) and odds ratios (ORs).
HRs and ORs were calculated for FOLFIRI plus cetuximab versus
FOLFIRI alone. ForOSandPFS,HRs and95%CIs for treatment comparisons
were calculated using univariable Cox proportional hazards models. Median
survival times were estimated using the Kaplan-Meier method12 (product-
limit estimates), and P values were calculated using log-rank tests. For
objective response, treatment groups were compared using Cochran-Mantel-
Haenszel tests. All analyses, apart from those for different cutoff values as
presented in the forest plots, were stratified according to Eastern Cooperative
Oncology Group performance status and region, as assigned through the
interactive voice response system at random assignment.
RESULTS
Patients and Samples
Of the 666 CRYSTAL study patients with tumors previously
typed as KRAS exon 2 wild type, RAS tumor mutation status was
evaluable in 430 (64.6%; Fig 1). Samples from the remaining 236
patients were not evaluable, either because of insufficient residual
DNA or because of the failure of  1 mutation assay. Using a 5%
mutant/wild-type cutoff, other RAS mutations were scored in 63
(14.7%) of 430 patients. Those with other RAS mutations were
grouped with patients previously classified as having tumors with
KRAS exon 2 mutations (n 397) to comprise a combined popu-
lation of patients with anyRASmutations (n 460). Using the less
stringent cutoff of 0.1%mutant/wild-type sequences, other RAS
mutations were scored in 86 (20.0%) of 430 patients. The most
common site of other RAS mutations was within KRAS exon 4
(Data Supplement).
Of 422 RAS/BRAF evaluable tumors, 46 (10.9%) were known
to carry BRAF mutations, all but one of which were scored as RAS
wild type; 315 (74.6%) of 422 tumors were wild type for both RAS
and BRAF.
Population
KRAS exon 2 wild type
KRAS exon 2 mutant
RAS evaluable
RAS wild type
RAS/BRAF wild type
Any RAS mutant
Other RAS mutant
Population
KRAS exon 2 wild type
KRAS exon 2 mutant
RAS evaluable
RAS wild type
RAS/BRAF wild type
Any RAS mutant
Other RAS mutant
666
397
430
367
315
460
63
0.70
1.17
0.58
0.56
0.53
1.10
0.81
0.80
1.04
0.75
0.69
0.70
1.05
1.22
IC %59n
IC %59n
0.56 to 0.87
0.89 to 1.54
0.44 to 0.77
0.41 to 0.76
0.37 to 0.75
0.85 to 1.42
0.39 to 1.67
0.67 to 0.95
0.83 to 1.28
0.60 to 0.93
0.54 to 0.88
0.54 to 0.91
0.86 to 1.28
0.69 to 2.16
HR
HR
666
397
430
367
315
460
63
Favors FOLFIRI +
cetuximab
0.35 0.7 1.0 1.4 2.3
Favors FOLFIRI
Favors FOLFIRI +
cetuximab
0.35 0.7 1.0 1.4 2.0
Favors FOLFIRI
A
B
Fig 2. Hazard ratios (HRs) for (A) overall
and (B) progression-free survival according
to tumor KRAS exon 2 and RAS mutation
status. FOLFIRI, fluorouracil, leucovorin,
and irinotecan.
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Comparability of Evaluable Populations
Baseline characteristics of the RAS-evaluable population and
RASwild-type andotherRAS-mutant subgroupswerebroadly similar
to those of the KRAS exon 2 wild-type subgroup of the KRAS popu-
lation (Table 1). However, and although balanced between treatment
groups, notably fewer patients with a tumor RAS mutation (68
[14.8%]of 460) had received prior adjuvant chemotherapy compared
with those with RAS wild-type tumors (82 [22.3%] of 367).
In relation toefficacy, therewasa trend forbetteroutcome for the
FOLFIRI-plus-cetuximab group compared with the FOLFIRI-alone
group in the RAS-evaluable population compared with the KRAS
exon 2wild-type population, with the differencemost pronounced in
relation to PFS and objective response (Table 2; Fig 2). Given the
similarity in baseline characteristics between the KRAS exon 2 wild-
type population and the RAS-evaluable subset, there was no obvious
selection bias thatmight have explained the increased cetuximabben-
efit in the RAS-evaluable population.
Efficacy According to RAS Mutation Status
A clear and significant benefit associated with the addition of
cetuximab to FOLFIRI was apparent in relation to OS, PFS, and
objective response in patients with RAS wild-type tumors (n 
367; efficacy outcome summarized in Table 2 and Figs 2 to 4). The
HR for OS time and OR for objective response rate were more
favorable toward FOLFIRI plus cetuximab in the RAS wild-type
population than in theRAS-evaluable population. Setting aside the
possible issue of selection bias, results for the RAS wild-type/BRAF
wild-type population were similar to those of the RAS wild-type
population (Data Supplement). For patients with tumors harbor-
ing other RAS mutations (n  63), no clear cetuximab treatment
benefit was apparent. Efficacy outcomes were also investigated for
the group of patients with any RAS mutation (n 460). No clear
difference in efficacy outcome between treatment groups was ap-
parent in this population.
BEAMing analysis allowed for the detection of tumor RAS
mutations at low prevalence. Using a more sensitive threshold of
0.1% to call mutations, 23 (5.3%) of 430 tumors classified as RAS
wild type when using a 5% cutoff were instead scored as RAS
mutant. Efficacy outcomes were reassessed in RAS wild-type and
RAS-mutant populations, as defined according to this 0.1% cutoff
(Data Supplement). As for the 5%cutoff analysis,HRs andORs did
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Fig 3. Overall survival according to treatment group in RAS populations. (A) KRAS codon 12 or 13 wild type, evaluable for other RAS mutations. (B) RAS wild type
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not suggest a positive or negative effect on efficacy associated with
the addition of cetuximab to FOLFIRI in patients with tumor
RAS mutations.
Treatment outcome in other RAS-mutant populations defined
according to cutoff values of 20%, 10%, 5%, 1%, and 0.1% were
visualized using forest plots ofHRs forOS and PFS times andORs for
objective response rates (Data Supplement). These plots suggested
that there was a relationship between the fraction of RAS-mutated
neoplastic cells in a tumor and the strength of EGFR-targeted therapy
resistance and that patients with other tumor RAS mutation signals
between 0.1% and  5% may have benefited from the addition of
cetuximab to FOLFIRI.
Safety
The overall incidence of adverse events according to treatment
groupwasbroadly similar across theKRAS andRAS subgroups (Table
3). In addition, the incidence of commonly reported adverse events in
each treatment group was also generally similar across these popula-
tions and in line with expectations.
DISCUSSION
The aim of our post hoc analysis of the CRYSTAL study was to
investigate the impactofRASmutationsother thanKRAS codon12or
13 in relation to treatment effects. In the evaluable patients with other
tumorRASmutations, therewasnoclear evidence that the additionof
cetuximab to FOLFIRI modified efficacy outcome. However, given
the relatively small number of patients in this group, no definitive
conclusions on the negative predictive value of other RAS mutations
can be drawn. In the combined group of patients with any RAS
mutation (KRAS exon 2 or other RAS), there was no indication that
the addition of cetuximab to FOLFIRI either improved or worsened
outcome. The absence of a negative effect in the RAS-mutant sub-
group when cetuximab was combined with FOLFIRI in our study
contrasts strongly with the data from the OPUS13 and PRIME7 RAS
investigations, which suggested worse outcome in the RAS-mutant
subgroups associated with the addition of cetuximab (PFS: HR, 1.54;
95%CI, 1.04 to 2.29) or panitumumab (PFS: HR, 1.31; 95%CI, 1.07
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Fig 4. Progression-free survival according to treatment group in RAS populations. (A) KRAS codon 12 or 13 wild type, evaluable for other RAS mutations. (B) RAS
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to 1.60 and OS: HR, 1.25; 95% CI, 1.02 to 1.55), respectively, to
FOLFOX4.However, our data are in line with findings in the second-
line setting, which showed that there was no negative effect of com-
bining panitumumab with FOLFIRI for patients with KRAS exon
2–mutant or other RAS-mutant tumors.14,15 Furthermore, on the
basis of the findings from these studies, current clinical guidelines
recommend that only patients with RAS wild-type tumors should be
treated with cetuximab or panitumumab in combination with
FOLFIRI or FOLFOX chemotherapy.16
In patientswithRASwild-type tumors, a clear cetuximab benefit
was seenacross efficacyendpoints.However, it shouldbenoted in this
context that an increased cetuximab benefit was apparent in theRAS-
evaluable subgroup, compared with the overall KRAS exon 2 wild-
type population, regardless of RAS status. Despite the similarity of
baseline characteristics, selection bias in relation to theRAS-evaluable
subgroup cannot be excluded.
The method selected to screen for RAS mutations was the
BEAMing technique.9 Although this approach can detect KRAS exon
2 mutations at a level of 0.01% mutant to wild-type sequences,17 a
higher thresholdof5%wasused inourRAS study.This isbroadly in
line with the sensitivity of other techniques such as next-generation
sequencing, pyrosequencing, and dideoxy nucleotide sequencing,
which may be used clinically to determine RAS mutation status. Be-
cause the fraction of neoplastic cells and ploidy status were not taken
into account, the percentage of mutated cells cannot be estimated.
Using this cutoff, RAS mutations were scored in 14.7% of evalu-
able CRYSTAL study patients with KRAS exon 2 wild-type tumors.
This frequency is similar to those reported in other first-line mCRC
studies, which used pyrosequencing or dideoxy sequencing/WAVE
analysis.7,18,19 In commonwith these studies and also the parallelRAS
analysis of the OPUS study,13 the most common location of RAS
mutations outside of KRAS exon 2 in CRYSTAL study patients was
KRAS exon 4. Also of interest in relation to the mutation profile was
thatNRAS exon4 tumormutations,whichwere scored in fourCRYS-
TAL study patients when using the 5% cutoff and in 12 patients when
using the 0.1% cutoff, had not to our knowledge been reported previ-
ously in the tumors of patients receiving first-line treatment for
mCRC. NRAS exon 4 tumor mutations were also seen in the OPUS
studyRAS analysis,13 inwhich an identical BEAMingmutation detec-
tion approach was used; again, the incidence was higher when 0.1%
rather than5%wasusedasacutoff. Itmaybe that suchmutations tend
to be of low prevalence and, although present, may not have been
detected by other screening technologies.
Because the significance of low-prevalence KRAS or RAS muta-
tions in relation to the effectiveness of EGFR antibody therapy in
mCRC is not clear,20-23 we also explored treatment outcome in RAS
subgroups defined according to a threshold of 0.1%mutant to wild-
type sequences. The effect of using the lower cutoff (higher sensitivity
in relation tomutation identification) was tomove 23 patients previ-
ously classified asRASwild type to themutant group. This resulted in
essentially no change in the HRs or ORs for FOLFIRI plus cetuximab
over FOLFIRI alone in the revised RAS wild-type population and
marginally better outcome for the FOLFIRI-plus-cetuximab group in
the revised other RAS-mutant population. These data are therefore
consistent with patients with low-prevalence mutations (between
0.1% and  5% mutant to wild type) deriving a treatment benefit
from the addition of cetuximab to FOLFIRI. This conclusion is in line
with thefindings froma retrospective studyof 95patientswithmCRC
Table 3. Most Common Grade 3 to 4 AEs in RAS Subgroups of Safety Population
AE
KRAS Exon 2 Wild Type
Any RAS Mutation
(n  460)†
Overall
(N  666)
RAS Evaluable
(n  430)†
RAS Wild Type
(n  367)†
Other RAS Mutation
(n  63)†
FOLFIRI

Cetuximab
(n  316)
FOLFIRI
(n  350)
FOLFIRI

Cetuximab
(n  210)
FOLFIRI
(n  220)
FOLFIRI

Cetuximab
(n  178)
FOLFIRI
(n  189)
FOLFIRI

Cetuximab
(n  32)
FOLFIRI
(n  31)
FOLFIRI

Cetuximab
(n  246)
FOLFIRI
(n  214)
No. % No. % No. % No. % No. % No. % No. % No. % No. % No. %
Any 257 81.1 211 60.3 169 80.5 131 59.5 144 80.9 110 58.2 25 78.1 21 67.7 189 76.8 133 62.1
MedDRA preferred term
Neutropenia 97 30.6 83 23.7 64 30.5 46 20.9 55 30.9 38 20.1 9 28.1 8 25.8 62 25.2 58 27.1
Diarrhea 52 16.4 35 10.0 29 13.8 20 9.1 26 14.6 18 9.5 3 9.4 2 6.5 30 12.2 22 10.3
Rash 28 8.8 0 0.0 19 9.0 0 0.0 16 9.0 0 0.0 3 9.4 0 0.0 19 7.7 0 0.0
Leucopenia 25 7.9 17 4.9 15 7.1 10 4.5 15 8.4 7 3.7 0 0.0 3 9.7 12 4.9 13 6.1
Fatigue 14 4.4 20 5.7 12 5.7 11 5.0 12 6.7 9 4.8 0 0.0 2 6.5 16 6.5 5 2.3
Deep vein thrombosis 16 5.0 2 0.6 11 5.2 2 0.9 11 6.2 1 0.5 0 0.0 1 3.2 2 0.8 9 4.2
Dermatitis acneiform 16 5.0 0 0.0 11 5.2 0 0.0 9 5.1 0 0.0 2 6.3 0 0.0 14 5.7 0 0.0
Composite categories
Skin reactions
Any 67 21.1 1 0.3 46 21.9 1 0.5 37 20.8 1 0.5 9 28.1 0 0.0 49 19.9 0 0.0
Acne-like rash 52 16.4 0 0.0 36 17.1 0 0.0 30 16.9 0 0.0 6 18.8 0 0.0 41 16.7 0 0.0
Infusion-related
reactions 5 1.6 0 0.0 4 1.9 0 0.0 4 2.2 0 0.0 0 0.0 0 0.0 7 2.8 0 0.0
NOTE. Reported at frequency of  5% in either treatment group of KRAS exon 2 wild-type subgroup of safety population and according to composite categories
of special interest.
Abbreviations: AE, adverse event; FOLFIRI, fluorouracil, leucovorin, and irinotecan; MedDRA, Medical Dictionary for Regulatory Activities.
According to MedDRA (version 10.0).
†According to MedDRA (version 12.0; except for composite categories).
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who had received EGFR antibody therapy, which indicated that the
PFS of patients with tumors with low-prevalence KRAS mutations
( 5%) was comparable to that of patients with KRAS wild-type
tumors.21 Using higher cutoff levels resulted in too few patients for
meaningful interpretations, butour forestplots suggest that thehigher
the fraction of mutated cells, the stronger the resistance to EGFR
antibody treatment. This would be in line with the hypothesis that
acquired resistance to such agentsmay result, at least in part, from the
outgrowth of small numbers of cells with existing RAS mutations.20
TheCRYSTAL study data are therefore consistent with 5%mutant
sequencesbeingapotentially appropriate cutoff value fordetermining
eligibility for FOLFIRI plus cetuximab as first-line treatment. Never-
theless, more data and more precise measurements of the fraction of
mutated neoplastic cells, as well as an accurate definition of the asso-
ciation between the fraction of mutated cells and resistance to EGFR
monoclonal antibodies, areneeded todefine theoptimal cutoff for the
clinical setting. This would require large collaborative studies using
common standardizedmethodologies for tumor processing and RAS
mutation detection.
In summary, our study supports the use of FOLFIRI plus cetux-
imab in patientswithRASwild-type tumors and, on the basis of a lack
of observed benefit, suggests the exclusion of patients with other RAS
mutations. Reserving such first-line treatment for a RAS wild-type
population allows the definition of a subgroup more likely to benefit
from the addition of cetuximab to FOLFIRI. Molecular testing of
tumors for all activatingmutations inKRAS andNRASbefore consid-
ering anti-EGFR therapy is therefore essential in selecting the most
effective treatment for patients with mCRC.
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